The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the leading inherited cause of mental retardation and autism spectrum disorders worldwide. It presents with a distinct behavioral phenotype which overlaps significantly with that of autism. Unlike autism and most common psychiatric disorders, the neurobiology of fragile X is relatively well understood. Lack of the fragile X mental retardation protein causes dysregulation of synaptically driven protein synthesis, which in turn causes global disruption of synaptic plasticity. Thus, FXS can be considered a disorder of synaptic plasticity, and a developmental disorder in the purest sense: mutation of the FMR1 (fragile X mental retardation 1) gene results in abnormal synaptic development in response to experience. Accumulation of this abnormal synaptic development, over time, leads to a characteristic and surprisingly consistent behavioral phenotype of attention deficit, hyperactivity, impulsivity, multiple anxiety symptoms, repetitive/perseverative/stereotypic behaviors, unstable affect, aggression, and self-injurious behavior. Many features of the behavioral and psychiatric phenotype of FXS follow a developmental course, waxing and waning over the life span. In most cases, symptoms present as a mixed clinical picture, not fitting established diagnostic categories. There have been many clinical trials in fragile X subjects, but no placebo-controlled trials of adequate size or methodology utilizing the most commonly prescribed psychiatric medications. However, large and well-designed trials of investigational agents which target the underlying pathology of FXS have recently been completed or are under way. While the literature offers little guidance to the clinician treating patients with FXS today, potentially disease-modifying treatments may be available in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model of autism: increased ratio of excitation/inhibition in key neural systems
Rubenstein, J. L. R., & Merzenich, M. M. (2003) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2003.00037.x · Cited by 2,768 · cited 1×
“Indeed, one frequently cited, unifying explanation for many causes of autism spectrum disorders is the disruption of excitatory/inhibitory circuit balance [Rubenstein and Merzenich, 2003].”
BackgroundThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“Recent findings have suggested that glutamatergic dysfunction most likely underlies the bulk of the CNS phenotype in FXS [Bear, 2005], and the ‘mGluR theory of fragile X’ [Bear et al., 2004] has received widespread acceptance.”
BackgroundAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
Weiler, I. J., Irwin, S. A., Klintsova, A. Y., Spencer, C. M., Brazelton, A. D., Miyashiro, K., Comery, T. A., Patel, B., Eberwine, J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5395 · Cited by 644 · cited 1×
“The seminal finding that FMRP is translated in response to synaptic activity [Weiler et al., 1997], mediated by metabotropic glutamate receptors, shifted research efforts to understanding the role of glutamatergic neurotransmission.”
BackgroundAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Self-citationGibson, J. R., Bartley, A. F., Hays, S. A., & Huber, K. M. (2008) · Journal of Neurophysiology · doi:10.1152/jn.90752.2008 · Cited by 529 · cited 1×
“Results appear to vary significantly by brain region, but excitatory (glutamatergic) drive onto inhibitory interneurons in the somatosensory cortex of Fmr1 knockout mice is deficient [Gibson et al., 2008], resulting in decreased inhibitory circuit function.”
BackgroundSuppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · cited 1×
“Extensive preclinical validation in animal models of FXS [Yan et al., 2005; Dölen et al., 2010] has led to clinical trials of potentially disease-modifying agents which antagonize metabotropic glutamate receptors.”
BackgroundSelf-citationKing, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 1×
“Minocycline also inhibits matrix metalloproteinase 9, which is excessively activated via mGluR5 in fragile X animal models [Bilousova et al., 2009].”
BackgroundMotivation Deficit in ADHD is Associated with Dysfunction of the Dopamine Reward Pathway
Volkow, N. D., Wang, G.-J., Newcorn, J. H., Kollins, S. H., Wigal, T. L., Telang, F., Fowler, J. S., Goldstein, R. Z., Klein, N., Logan, J., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.97 · Cited by 429 · cited 1×
“Clinical symptoms of ADHD are generally considered to be manifestations of dysfunction in dopamine pathways regulating attention, impulse control, and motivation [Volkow et al., 2010].”
Background
Cited by
Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review
Instanes, J. T., Klungsøyr, K., Halmøy, A., Fasmer, O. B., & Haavik, J. (2018) · Journal of Attention Disorders · doi:10.1177/1087054716669589 · Cited by 232
Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice
Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100
Modeling autism-relevant behavioral phenotypes in rats and mice: Do ‘autistic’ rodents exist?
Servadio, M., Vanderschuren, L. J. M. J., & Trezza, V. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000163 · Cited by 76
Kiser, D. P., Rivero, O., & Lesch, K. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12392 · Cited by 58
“…inventory of severe symptoms, ranging from cognitive impairment to hyperactivity, as well as language, emotion regulation and motor deficits, resulting in 25–35% of the affected individuals also meeting criteria for ASD (Belmonte & Bourgeron, 2006; Lisik & Siero n, 2010; Tranfaglia, 2011).”
BackgroundPathological plasticity in fragile X syndrome.
Martin, B. S., & Huntsman, M. M. (2012) · Neural Plasticity · doi:10.1155/2012/275630 · Cited by 57
Metadata
- Authors
- Tranfaglia, M. R.
- Venue
- Developmental Neuroscience
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 33
- Issue
- 5
- Pages
- 337-348
- ISSN
- 0378-5866 (ISSN-L)
- 1421-9859
- OpenAlex
- W2063945964
- Cited by
- 89
- References
- 35
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome. https://app.cochat.ai/papers/10.1159/000329421
- The paper
- Tranfaglia, M. R. (2011). The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome. Developmental Neuroscience. https://doi.org/10.1159/000329421
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.